GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an

CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.

GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.

CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech

Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears